Alpha-Defensins
Research OnlyA family of small cationic antimicrobial peptides (29-35 amino acids) that are key components of innate immunity in humans. Produced primarily by neutrophils (HNP-1 to 4) and Paneth cells (HD-5, HD-6), they exhibit broad-spectrum antimicrobial activity and immunomodulatory functions. Well-characterized biochemically with extensive research, though therapeutic development faces challenges.
HNP-1 · HNP-2 · HNP-3 · HNP-4 · HD-5 · HD-6 · Human Neutrophil Peptides · Human Defensins
40 human studies
- Preclinical
- 80%
- Clinical
- 20%
Based on 200 cited sources
Demonstrated effect magnitude — not a recommendation or safety claim.
Research depth: abundant controlled observational human data (Crohn's, HIV, dyslipidemia biomarker cohorts) but no RCT of defensin administration for efficacy. Mechanism: membrane disruption, nanonet self-assembly, and chemotaxis well characterized in vivo. Plausibility: mechanism-to-surrogate solid; in-vivo translation limited by salt sensitivity. Global coverage: robustly replicated across many independent groups and countries; no regulatory approval. Community: endogenous peptides with negligible documented exogenous use. Effectiveness not-established: no quantified human efficacy estimate for administered defensins and no meaningful community effect signal.
Alpha-defensins are endogenous antimicrobial peptides with well-characterized mechanisms supported by extensive structural and functional studies from multiple independent research groups worldwide.
How It Works (Simplified)
Alpha-defensins function as key effectors of innate immunity through several pathways:
Cationic peptides bind to anionic microbial membranes, insert into lipid bilayer, and form pores causing ion leakage and cell death.
Recruit and activate immune cells including T cells and dendritic cells, bridging innate and adaptive immunity responses.
HD-6 self-assembles into fiber structures that physically trap bacteria, representing a unique non-lytic defense mechanism.
Directly inactivate viral particles, block entry receptors, and interfere with fusion to inhibit viral replication.
Key Research: Selsted ME et al. (UCLA, 1985) first characterized HNP structure and antimicrobial mechanism. PMID:4056036
Important Limitations
- Salt sensitivity reduces antimicrobial activity in physiological conditions (150 mM NaCl)
- In vitro MIC values may overestimate in vivo efficacy
- No alpha-defensin therapeutics currently approved despite decades of research
- High synthesis cost due to complex disulfide bonding (3 intramolecular bonds)
- Concentration-dependent cytotoxicity may limit therapeutic window
Alpha-defensins are released within seconds to minutes during neutrophil degranulation or Paneth cell secretion. Antimicrobial activity is immediate upon contact with target pathogens. Membrane disruption occurs within minutes of peptide-pathogen interaction.
PMID:4056036Chemotactic signaling begins, recruiting additional immune cells to sites of infection. Immunomodulatory effects on dendritic cells and T cells initiate within hours of defensin release.
PMID:8621683Sustained antimicrobial defense through continued neutrophil recruitment and Paneth cell secretion. HD-6 nanonet formation provides ongoing physical barrier against intestinal pathogens.
PMID:22722251Long-term defensin deficiency (as seen in Crohn's disease) associated with dysbiosis and increased susceptibility to intestinal infections. Therapeutic supplementation timelines are not established due to lack of clinical trials.
PMID:17709525Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
LL-37
SynergisticBoth are cationic antimicrobial peptides with complementary mechanisms. Alpha-defensins and LL-37 may work synergistically to provide broad-spectrum antimicrobial coverage. No direct clinical studies on combination.
Beta-Defensins
CompatibleDifferent tissue distribution (alpha-defensins in neutrophils/Paneth cells vs beta-defensins in epithelial cells). Complementary innate immunity coverage with no known contraindications.
Thymosin-Alpha-1
CompatibleAlpha-defensins provide direct antimicrobial action while Thymosin Alpha-1 modulates adaptive immunity. Theoretical complementary benefits for immune function.
BPC-157
CompatibleNon-overlapping mechanisms. Alpha-defensins focus on antimicrobial defense while BPC-157 targets tissue repair. No interaction studies available.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Alpha-Defensins
Related Peptides
KPV
Lys-Pro-Val · Lysine-Proline-Valine · alpha-MSH(11-13) +1
A naturally occurring tripeptide derived from the C-terminus of alpha-melanocyte-stimulating hormone (alpha-MSH). Preclinical studies demonstrate potent anti-inflammatory effects via NF-kB inhibition, but no human clinical trials have been conducted. Research has focused on inflammatory bowel disease and skin inflammation models.
Kristagen
EDG · Glu-Asp-Gly · Immune tripeptide
A synthetic tripeptide (Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson, claimed to regulate thymus function and support immune cell differentiation. No Western clinical validation exists; research is limited to Russian preclinical studies.
Lactoferricin
LFcinB · Lactoferricin B · LfcinB +1
An antimicrobial peptide derived from lactoferrin, a protein found in milk and other secretions. Shows broad-spectrum antimicrobial activity in laboratory studies. Research focuses on potential applications in infectious disease, food safety, and cancer. Primarily studied preclinically with very limited human clinical data. Not approved as a therapeutic by any regulatory agency.
Murepavadin
POL7080 · RG7929
A first-in-class cyclic antimicrobial peptide targeting the LptD outer membrane protein of Pseudomonas aeruginosa. The first OMPTA (outer membrane protein targeting antibiotic) to reach clinical development. IV formulation discontinued due to nephrotoxicity; inhaled formulation continues Phase 3 development for cystic fibrosis and bronchiectasis patients.
Thymalin
Thymulin · Thymic Factor · Timalin +1
A thymic peptide complex developed in Russia and used clinically in the former Soviet Union for immunomodulation. Derived from calf thymus extract, it contains multiple peptides claimed to restore immune function. Approved in Russia since the 1970s but not recognized by Western regulatory agencies. Evidence comes primarily from Russian studies with limited Western replication.
Thymogen
Glu-Trp · EW dipeptide · Timogen +2
A synthetic dipeptide (glutamyl-tryptophan) developed in Russia as a defined successor to thymalin. Approved in Russia for immunomodulation with extensive Russian clinical literature. Represents an attempt to create a standardized, synthetic thymic peptide. Not approved by Western regulatory agencies.